CTOs on the Move


 
MiraMed Global Services stands as the premier global provider of business process outsourcing solutions to healthcare organizations nationwide. MiraMed partners with hospitals, health networks, physician practices and related industry service organizations to provide a broad portfolio of customizable solutions, uncover and capitalize on hidden financial opportunities, improve productivity and ultimately increase profits. The key to MiraMed`s success is its unique business model that has evolved over the last twenty-five years. Under this model, MiraMed pairs healthcare industry experts with world-class processes, infrastructure and technology to deliver meaningful and measurable results. This proprietary model enables sustainable change by delivering a complete, ...
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.miramedgs.com
  • 255 West Michigan Avenue
    Jackson, MI USA 49201
  • Phone: 866.544.6647

Executives

Name Title Contact Details

Similar Companies

Take Care Health Employer Solutions

Take Care Health Employer Solutions is a Conshohocken, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Breathe California

Breathe California is a Daly City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Steininger Behavioral Care Services

Steininger Behavioral Care Services is a Cherry Hill, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Centric Medical Communications

Centric Medical Communications, Inc. is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ContraVir Pharmaceuticals, Inc

ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.